Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules

PURPOSE: Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) were tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose pembrolizumab with two other alternative ipilimumab reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Georgina V., Robert, Caroline, Butler, Marcus O., Couture, Felix, Carlino, Matteo S., O'Day, Steven, Atkinson, Victoria, Cebon, Jonathan S., Brown, Michael P., Dalle, Stéphane, Hill, Andrew G., Gibney, Geoffrey T., McCune, Steven, Menzies, Alexander M., Niu, Cuizhen, Ibrahim, Nageatte, Moreno, Blanca Homet, Diab, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401495/
https://www.ncbi.nlm.nih.gov/pubmed/34210681
http://dx.doi.org/10.1158/1078-0432.CCR-21-0793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401495/
https://www.ncbi.nlm.nih.gov/pubmed/34210681
http://dx.doi.org/10.1158/1078-0432.CCR-21-0793

Ejemplares similares